At CRISPR Therapeutics, we are developing allogeneic CAR-T cells utilizing the precision and efficiency of gene-editing. CRISPR/Cas9 technology is intended to facilitate the generation of allogeneic cellular products, enhance immune performance and speed the discovery and generation of novel therapeutics. Our initial allogeneic gene-edited CAR-T candidates are currently under investigation in clinical studies that focus on validated targets for hematologic malignancies and in solid tumors. The efficacy and safety of these candidates has not been established and are not approved by the FDA.